Metis Global Partners LLC Has $508,000 Stake in Illumina, Inc. (NASDAQ:ILMN)

Metis Global Partners LLC raised its position in Illumina, Inc. (NASDAQ:ILMN) by 6.4% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 3,803 shares of the life sciences company’s stock after purchasing an additional 228 shares during the quarter. Metis Global Partners LLC’s holdings in Illumina were worth $508,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently modified their holdings of ILMN. WCM Investment Management LLC raised its stake in shares of Illumina by 26.6% in the 4th quarter. WCM Investment Management LLC now owns 4,129,855 shares of the life sciences company’s stock valued at $551,625,000 after purchasing an additional 867,673 shares during the period. ARK Investment Management LLC acquired a new stake in shares of Illumina in the fourth quarter valued at about $91,714,000. Massachusetts Financial Services Co. MA increased its position in shares of Illumina by 148.6% in the third quarter. Massachusetts Financial Services Co. MA now owns 1,056,172 shares of the life sciences company’s stock valued at $137,735,000 after acquiring an additional 631,294 shares during the last quarter. Janus Henderson Group PLC increased its position in shares of Illumina by 40.5% in the third quarter. Janus Henderson Group PLC now owns 2,168,057 shares of the life sciences company’s stock valued at $282,735,000 after acquiring an additional 625,245 shares during the last quarter. Finally, Sumitomo Mitsui Trust Group Inc. increased its position in shares of Illumina by 116.9% in the fourth quarter. Sumitomo Mitsui Trust Group Inc. now owns 865,546 shares of the life sciences company’s stock valued at $115,663,000 after acquiring an additional 466,519 shares during the last quarter. Institutional investors and hedge funds own 89.42% of the company’s stock.

Illumina Trading Up 0.9 %

ILMN opened at $85.69 on Thursday. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.77 and a quick ratio of 1.42. Illumina, Inc. has a fifty-two week low of $80.18 and a fifty-two week high of $156.66. The firm has a market capitalization of $13.57 billion, a PE ratio of -11.16, a P/E/G ratio of 1.60 and a beta of 1.17. The company’s 50-day moving average is $120.36 and its 200 day moving average is $132.17.

Illumina (NASDAQ:ILMN) last posted its earnings results on Thursday, February 6th. The life sciences company reported $0.86 earnings per share for the quarter, missing analysts’ consensus estimates of $0.92 by ($0.06). Illumina had a positive return on equity of 13.37% and a negative net margin of 27.95%. As a group, research analysts predict that Illumina, Inc. will post 4.51 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of analysts recently issued reports on the company. Royal Bank of Canada lowered their target price on Illumina from $250.00 to $247.00 and set an “outperform” rating on the stock in a research report on Friday, February 7th. TD Cowen downgraded Illumina from a “buy” rating to a “hold” rating and lowered their target price for the company from $177.00 to $140.00 in a research report on Friday, February 7th. Citigroup lowered their target price on Illumina from $130.00 to $90.00 and set a “neutral” rating on the stock in a research report on Tuesday. Hsbc Global Res cut Illumina from a “strong-buy” rating to a “hold” rating in a report on Friday, February 28th. Finally, HSBC cut Illumina from a “buy” rating to a “hold” rating and set a $100.00 price target for the company. in a report on Friday, February 28th. One equities research analyst has rated the stock with a sell rating, ten have given a hold rating, ten have given a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, Illumina presently has a consensus rating of “Moderate Buy” and a consensus target price of $149.25.

Illumina Company Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.